Argenx Se Stock Price, News & Analysis

argenx has announced that underwriters have fully exercised their option to purchase an additional 350,000 ordinary shares as part of a global offering, raising the total anticipated gross proceeds to approximately $805 million from 2,683,334 ordinary shares.

The offering, managed by J.P. Morgan and others, follows a filing with the SEC under an automatically effective shelf registration statement. This press release serves as informational and does not constitute an offer to sell securities.

argenx SE, a global immunology company, will hold its annual general meeting of shareholders on May 10, 2022, at Hilton Amsterdam Airport Schiphol. Important agenda items include re-appointments to the Board of Directors, discussion of the 2021 Annual Accounts, and an advisory vote on the 2021 remuneration report. Shareholders are encouraged to use electronic proxy voting. The full agenda and documents related to the meeting are available on the argenx website.

argenx SE has successfully completed a global offering, closing the sale of 2,333,334 ordinary shares for gross proceeds of approximately $700 million (around €637 million). The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley. The shares are listed on the regulated market of Euronext Brussels. This offering allows argenx to advance its pipeline of antibody-based medicines aimed at severe autoimmune diseases, bolstering its commitment to improving patient lives.

argenx SE has announced a global offering of ordinary shares, including American Depository Shares (ADSs), aimed at raising approximately $700 million (about €637 million). The offering includes 1,551,044 ADSs priced at $300 each and 782,290 ordinary shares at €273.10 each. The anticipated closing date is March 28, 2022, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 350,000 shares. The offering is designed to support argenx's mission in treating severe autoimmune diseases.

argenx SE has initiated a global offering of $500 million in ordinary shares, potentially represented by American Depository Shares (ADSs). This offering includes a public offering in the U.S. and a private placement in Europe. The offering aims to close on a simultaneous basis. Additionally, underwriters may purchase up to 15% more shares. Notably, Baillie Gifford has expressed interest in acquiring up to $170 million of shares. The offering is overseen by J.P. Morgan, Morgan Stanley, Cowen, and SVB Leerink, with securities offered under a previously filed SEC registration statement.

argenx SE (Euronext & Nasdaq: ARGX) announced positive topline results from the Phase 3 ADAPT-SC study, showing that subcutaneous efgartigimod achieved noninferior total IgG reduction in generalized myasthenia gravis patients compared to intravenous administration. The study met its primary endpoint with a 66.4% IgG reduction at day 29, versus 62.2% for VYVGART. The company plans to submit a Biologics License Application (BLA) to the FDA by the end of 2022, aiming to enhance treatment options for patients and address the need for individualized care.

argenx reported a transformational year in 2021, highlighted by the FDA approval and U.S. launch of VYVGART, the first FcRn blocker for generalized myasthenia gravis. Full-year revenue soared to $497.3 million, a substantial increase from $41.2 million in 2020, primarily due to collaboration agreements. However, operating losses decreased to $348.7 million from $477.6 million the previous year. The company anticipates utilizing up to half of its cash reserves in 2022 to support the global launch of VYVGART and expand its pipeline with new indications.

February 28, 2022 – argenx (Euronext & Nasdaq: ARGX) announced its participation in the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 2:10 p.m. E.T. Management will engage in a fireside chat during the event. Interested parties can access a live webcast via the Investors section of the argenx website, with a replay available for 90 days after the presentation. argenx specializes in creating innovative therapies for severe autoimmune diseases.

argenx (Euronext & Nasdaq: ARGX) announced a conference call on March 3, 2022, at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update. The call will be accessible via the Investors section on the company's website. A replay will be available for a year after the call. argenx focuses on developing innovative treatments for severe autoimmune diseases and has commercialized the first approved neonatal Fc receptor blocker in the U.S. and Japan.